Maartje van den Biggelaar: LSBR Awarded Our Consortium the LSBR Anniversary Grant of €1.6 Million to Launch HemoTwin-BD
Maartje van den Biggelaar, Head of laboratory of Proteomics at Sanquin, shared a post on LinkedIn:
“Proteomics of hemostasis
Extremely proud and happy that The Landsteiner Foundation for Blood Transfusion Research (LSBR) awarded our consortium the LSBR Anniversary Grant of €1.6 million to launch HemoTwin-BD, a multidisciplinary program to unravel why patients with inherited bleeding disorders or an unexplained bleeding tendency can have very different bleeding phenotypes.
This grant gives us the opportunity to combine large national patient studies and scientific expertise to investigate how genetic variationtranslates into proteoforms that shape the hemostatic potential. Using AI-based modelling we will build digital twins to uncover new biological mechanisms and ultimately pave the way for more personalized and safer treatment strategies.
A big thank you to all consortium partners—from clinical experts and fundamental researchers to data scientists—and to The Landsteiner Foundation for Blood Transfusion Research (LSBR) for their trust in our work.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS